Evusheld Archives -

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid,

NICE rejects five COVID drugs and backs three on price, efficacy data

https://pharmaphorum.com/news/nice-rejects-five-covid-drugs-and-backs-three-on-price-efficacy-data/

Half a million people in the UK with conditions like blood cancer that prevents them being protected from

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

https://pharmaphorum.com/news/astrazeneca-raises-2022-guidance-names-demare-as-non-exec-chair/

GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the

FDA restricts GSK’s Xevudy due to lower efficacy against BA.2

https://pharmaphorum.com/news/fda-restricts-gsks-xevudy-due-to-lower-efficacy-against-ba-2/

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted

AZ halts development of Beta variant COVID-19 vaccine

https://pharmaphorum.com/news/az-halts-development-of-beta-variant-covid-19-vaccine/

AstraZeneca’s antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be

AZ’s antibody first to be cleared by FDA for COVID prevention

https://pharmaphorum.com/news/azs-antibody-first-to-be-cleared-by-fda-for-covid-prevention/

Evusheld